novel -1260 C > T polymorphism and haplotype 3 (-1697G, -1260T, -719C, and -719C) of the RET gene were associated with the risk of lung cancer

identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.

RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations.

RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics.

RET rearrangements were recently identified in a subset of lung adenocarcinomas by several groups using different screening strategies.

RET rearrangements have been identified in 1 to 2% of patients with adenocarcinoma or adenosquamous carcinoma of the lung. KIF5B-RET is the predominant RET fusion in NSCLC, although other RET fusions have been reported

RET fusions occur in a small percentage of lung adenocarcinomas, representing a new targetable driver gene. [Review]

ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.

RET fusions may represent a genetic mechanism of radiation-induced lung adenocarcinoma.

The RET rearrangements were observed in 1.2% of non-small-cell lung carcinoma. All cases of RET rearrangement were adenocarcinomas.

ALK, ROS1 and RET fusions are associated with pathological features of lung adenocarcinoma and are more prevalent in solid-predominant adenocarcinoma.

Our data suggest that KIF5B-RET promotes the cell growth and tumorigenicity of non-small cell lung cancers through multilevel activation of STAT3 signaling, providing possible strategies for the treatment of KIF5B-RET positive lung cancers.

subpopulation of SCLC patients may derive benefit from tyrosine kinase inhibitors targeting RET. Coupled with the presence of RET fusion proteins in non-small-cell lung cancer, our data indicate an emerging role for RET in SCLC.

Studies indicate that RET proto-oncogene fusion gene occurred predominantly in Asian females with younger age, in non-smokers, and in lung adenocarcinomas patients.

data suggest one-step screening platform for KIF5B-RET as well as EGFR, K-RAS, ALK oncogenic mutations be necessary for lung adenocarcinoma patients

RET mutation is associated with lung neuroendocrine carcinoma in MEN2B.

lung adenocarcinomas with RET and ROS1 fusions share many radiographic features.

RET gene rearrangement is associated with lung cancer.

our study suggested that the prevalence of ALK, ROS1 and RET fusions is very rare in lung squamous cell carcinoma patients.

Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered.

Data suggest that the KIAA1217-RET-fusion gene is a promising target for lung cancer treatment.

The frequencies of ALK, ROS1 and RET rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical characteristics are similar to those in lung adenocarcinoma. Fusions of the above 3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients.

Detection of Gene Rearrangements in Circulating tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell lung cancer and ERG-Rearrangements in Prostate cancer.(

RET gene alterations (copy number gain and rearrangement) exist in all RET-positive samples. RET-positive expression is a relatively independent factor in non-small cell lung cancer cases(NSCLC) patients, which indicates that the RET gene may be a novel target site for personalized treatment of NSCLC.

RET rearrangement is associated with lung adenocarcinoma.

loss of a single lamin B1 allele induced spontaneous lung tumor formation and RET activation.

the clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients with RET rearrangements were analyzed.

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.

Unique Genetic Characteristics and Clinical Prognosis of Female Patients with lung cancer Harboring RET Fusion Gene.

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.